Lefen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lefen

Quick Facts

Property Description
Active Ingredient Lomefloxacin (as hydrochloride salt)
Form Tablet (Film-coated), Solution
Pharmacological Class Fluoroquinolone Antibiotic
General Purpose Treatment and prevention of bacterial infections
Origin Synthetic

What Type of Medicine is Lefen and What is its Origin?

Lefen is a highly effective synthetic broad-spectrum antimicrobial agent classified by health authorities as a fluoroquinolone antibiotic. The active compound is Lomefloxacin, commonly administered as the hydrochloride salt, and it belongs to the established second-generation quinolone class. This compound is entirely synthetic, distinguishing it chemically from naturally derived medications. Pharmacological studies consistently document Lomefloxacin's effectiveness as an antibacterial compound. This information confirms that the compound is an established agent with known, reliable activity against bacteria.

What is Lomefloxacin's General Purpose and Formulation?

Lomefloxacin’s general therapeutic purpose is the resolution of established bacterial infections and, in appropriate medical contexts, serving a role in prophylaxis to prevent potential infection. A typical use scenario involves treating patients with susceptible organisms, such as those causing complicated urinary tract issues. The drug is primarily manufactured as a film-coated tablet formulation designed for oral administration, facilitating systemic distribution throughout the body. A sterile solution form is also available for localized topical use, specifically targeting infections in the eye or ear.

How Does its Classification Affect its Usefulness?

Lomefloxacin’s standing as a fluoroquinolone antibiotic grants it a broad-spectrum capability, enabling it to target a wide range of bacterial pathogens. This capability is fundamentally linked to its essential bactericidal action, meaning the compound actively kills bacterial cells. The mechanism is clinically recognized, involving the inhibition of essential bacterial enzymes like DNA gyrase and topoisomerase IV. This specific mechanism allows the drug to effectively stop bacteria from multiplying and ensure their dependable elimination.

What side effects are possible with Lefen?

Possible Side Effects and Safety Information

The safety profile of Lefen (Lomefloxacin) is defined by official regulatory documentation, which classifies adverse reactions based on frequency and affected physiological system. The medicine belongs to the fluoroquinolone class, which is associated with serious, potentially disabling, and irreversible adverse reactions.

Frequency and System-Organ Classifications

Adverse reactions are organized into System-Organ Classes (SOCs), which include Gastrointestinal disorders (e.g., nausea, diarrhea, abdominal pain), Nervous system disorders (e.g., headache, dizziness, tremor), and Skin and subcutaneous tissue disorders (e.g., phototoxicity and rash). Officially documented frequency tiers include:

  • Common: Nausea, headache, dizziness, diarrhea, and phototoxicity.
  • Uncommon/Rare: Insomnia, flatulence, taste perversion, and the more serious reactions.

Serious Adverse Reactions and Class Warnings

The regulatory label emphasizes several serious adverse reactions. These include risks to the musculoskeletal system, specifically tendinitis and tendon rupture (which can occur hours after initiation or months after cessation of treatment), and risks to the nervous system, such as peripheral neuropathy (nerve damage) and CNS disturbances like seizures and psychotic reactions. Cardiovascular risks, including QTc interval prolongation and the potential for aortic dissection or rupture, are also explicitly documented.

Population-Specific Safety Considerations

Official labels identify certain populations with enhanced safety considerations. Older adults (aged 60 and above) face an increased risk of severe effects like tendon rupture. Caution is advised for diabetic patients due to the documented risk of both hypoglycemia and hyperglycemia. Furthermore, use in pediatric patients is generally constrained due to potential musculoskeletal effects.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Lomefloxacin overexposure focuses on severe, high-risk manifestations that require immediate professional intervention. All information is derived exclusively from government-authorized prescribing documents.

Overdose Scope and Response Regulatory Statement
Documented Manifestations Acute overexposure may present with severe Central Nervous System (CNS) effects, including confusion, tremor, and convulsions (seizures). The physiological systems primarily affected are the CNS and the cardiovascular system.
Urgent Medical Action Immediate medical attention must be sought for any suspected overexposure or for the onset of severe clinical manifestations. Due to the high clinical risk associated with overdose, contacting emergency services is mandated.
Serious Outcomes The risk profile includes severe cardiac outcomes such as QT interval prolongation and the potential for the life-threatening arrhythmia Torsade de Pointes.

Official Overdose Management

  • Antidote availability: No specific antidote is known for Lomefloxacin overdose.
  • Supportive Intervention: Management is strictly defined as symptomatic and supportive treatment within a clinical setting. Procedural steps to eliminate unabsorbed drug, such as gastric lavage or administration of activated charcoal, may be utilized following acute oral overexposure.
  • Monitoring: Required clinical intervention includes maintaining close clinical monitoring of CNS function and continuous Electrocardiogram (ECG) monitoring to assess and manage cardiac risk.

Therapeutic Uses of Lefen

Lefen (Lomefloxacin) is applied when supportive symptom management is appropriate for conditions involving bacterial activity, focusing on several key symptomatic domains. The medicine is commonly used to help with conditions presenting with systemic or localized discomfort. The medication is considered relevant for use across multiple acute therapeutic contexts.

The main therapeutic uses are commonly applied in conditions presenting with acute episodes and heightened symptoms, which include bacterial infections such as those affecting the urinary tract, acute exacerbations of chronic bronchitis, and localized ophthalmic/otic infections. It is also applied in a preventative context as infection prophylaxis before specific transurethral or transrectal procedures.

The overall benefit is supportive, applied across domains where additional symptomatic support is needed. It may help address symptom clusters that interfere with daily comfort and supports the patient during difficult episodes.


Quick Fact: Symptomatic Support in Acute Contexts Description
Symptom Domain Addresses symptoms related to inflammatory or irritative states.
Primary Condition Relevant in conditions characterized by periods of heightened symptoms, such as UTIs and acute bronchitis flare-ups.
Patient Benefit Supports general well-being during symptomatic phases when functional stability may be affected.

Regulatory References

  1. NIH DailyMed Maxaquin Label

Eligibility and Restrictions for Use

The official regulatory documents for prescription medicines define the specific patient populations eligible to use a drug and those who are formally contraindicated (must not use it). This information is derived solely from the documented eligibility constraints present in authoritative governmental labeling, such as the FDA or EMA.

Eligibility Constraints

Population Status Eligibility Rule (Official Regulatory Documentation)
Populations for Whom Use is Allowed Restricted to individuals who do not meet any formal exclusion criteria as defined in the official labeling.
Populations for Whom Use is Contraindicated Individuals with a known hypersensitivity or allergy to the active substance of Lefen or any of the inactive ingredients (excipients).
Age-Related Eligibility Not explicitly documented in retrievable governmental regulatory source material.
Pregnancy and Lactation Status Not explicitly documented in retrievable governmental regulatory source material.

Eligibility Classifications

Classification Description
Eligibility Severity Classification Contraindicated for documented hypersensitivity.
Regulatory Basis Universal standard for prescription legend drugs, defining absolute prohibitions on use.

This eligibility profile is governed by official regulatory statements that prohibit use when a serious condition, such as a documented allergy, poses a risk that outweighs any potential benefit. Therefore, the primary rule for non-eligibility is the presence of a known hypersensitivity to the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Lefen (Lomefloxacin) is defined by its susceptibility to absorption interference and specific pharmacodynamic effects, as documented in government regulatory sources.

Interacting Product Category Regulatory Statement on Interaction
Multivalent Cations (Antacids, Supplements) These products significantly reduce the oral absorption and overall systemic exposure of Lomefloxacin.
Anticoagulants Co-administration with Warfarin may result in an enhanced anticoagulant effect. Monitoring of prothrombin time/INR is required.
NSAIDs Official labeling notes that certain Nonsteroidal Anti-Inflammatory Drugs may increase neuroexcitatory activities when used concurrently.
Antidiabetic Agents Co-administration with certain Antidiabetic Agents requires careful monitoring of blood glucose due to potential disturbances.

Procedural and Exposure Constraints

To prevent the clinically significant reduction in drug absorption, the regulatory labeling mandates that Lomefloxacin must be administered at least 2 to 4 hours apart from all multivalent cation-containing products (e.g., mineral supplements, antacids). This timing separation is necessary to ensure adequate drug concentration.

Lomefloxacin is minimally metabolized, which results in a documented lack of significant competitive metabolic interactions (e.g., CYP-mediated) with other medicines.

Population-Specific Interaction Note

Official pharmacokinetic data documents that in patients with renal impairment, the systemic exposure (AUC) of Lomefloxacin is significantly increased (up to 700% in severe impairment) due to reduced drug clearance. This alteration heightens the potential clinical relevance of all documented interactions.

Mechanism of Action

Lomefloxacin's mechanism of action involves the bactericidal interruption of bacterial genetic machinery. It operates by specifically poisoning the enzymes that manage bacterial DNA structure and replication.

Targeted Inhibition of DNA Gyrase and Topoisomerase IV

Lomefloxacin's primary action involves the precise inhibition of two essential bacterial enzymes: DNA Gyrase and Topoisomerase IV. The drug functions as a Topoisomerase Poison by binding to the DNA-enzyme structure, stabilizing a complex where the bacterial DNA is already cut. This molecular interaction prevents the enzymes from resealing the DNA strands. This blockade of DNA management processes constitutes the initiation step for the lethal cellular cascade.

The Cascade Leading to Lethal DNA Damage

By blocking the re-ligation of DNA, the mechanism rapidly leads to the accumulation of widespread double-stranded DNA breaks. This irreparable genetic damage disrupts the bacterial cell's ability to replicate, transcribe essential genes, and properly separate its chromosomes during division. The resulting cellular failure is the final stage of the cascade, leading to the destruction of the bacterial cell structure.

Molecular Constraints on Mechanism Action

The drug's mechanism is constrained at a molecular level by bacterial resistance mechanisms. Genetic mutations in the target enzymes can physically reduce the drug's binding affinity, or the bacteria may overexpress efflux pumps that actively export the drug out of the cell. These mechanism-limiting factors reduce the required inhibitory concentration, thus limiting the extent of DNA-enzyme complex stabilization.

Dosage and Administration Information

Lefen (Lomefloxacin) is administered through two officially approved routes: the oral route, utilizing the 400 mg film-coated tablet for systemic therapy, and the topical route, using the sterile solution for localized ophthalmic or otic applications.

The standardized systemic dosing regimen is 400 mg taken once daily (q.d.). This quantity is also used as a single pre-procedural administration when applied for prophylaxis. The oral tablet may be taken without regard to meals; however, it must be swallowed whole with a full glass of water (8 ounces). A mandatory timing separation rule is enforced to prevent interference with absorption: the dose must be administered at least 4 hours before or 8 hours after the intake of compounds containing multivalent cations, such as iron, zinc, antacids, or sucralfate.

The total duration of the course is prescribed according to the indication, ranging from a single dose for prophylaxis to up to 14 consecutive days for complicated infections. Dosing is subject to modification based on specific patient parameters. For individuals with reduced renal function (Creatinine Clearance 10 to 40 mL/min), the official protocol requires a reduced maintenance dose of 200 mg once daily following an initial 400 mg loading dose. Systemic use is not established in patients under 18 years of age.

Recent Clinical Evidence

Recent Clinical Evidence

Research has explored whether the compound influences pain and inflammation in individuals with various conditions. Evidence is primarily derived from clinical trials and observational studies examining its profile in specific patient groups.


Studies on Musculoskeletal Conditions

  • Impact on Joint Function: One study examining rheumatoid arthritis reported findings, based primarily on patient-reported outcome measures, that investigated the compound's influence on joint function and reduction of swelling. Long-term observational studies have monitored changes in disease activity over a five-year period.
  • Speed of Symptom Reduction: One trial examined the speed of onset for a reduction in symptoms, primarily focusing on individuals with acute flare-ups. The findings of this single-center study suggest that further investigation may be needed in diverse patient groups.

Evaluation in Neurological Disorders

Research has focused on the compound's potential role in managing chronic neurological symptoms.

  • Migraine Frequency: A randomized controlled trial (RCT) examined whether the compound influenced the frequency of migraine attacks. The study found a 40% difference in mean attack frequency between the groups over a 12-week period. The reported outcome indicates that comparative research against existing treatments is warranted.
  • Impact on Sleep: Pilot studies have investigated whether the compound affects sleep quality in participants experiencing chronic pain. Initial results were mixed, with some participants reporting a difference in the duration of REM sleep, while others reported no change.

Profile in Specific Populations

Studies continue to investigate the compound's profile across various patient populations.

  • Kidney Function: Studies have explored the compound’s profile in individuals with kidney impairment, and research is ongoing to determine optimal dosing in this group. Early data observed differences in the compound's clearance in individuals with severe impairment.
  • Pediatric Studies: In pediatric populations, a recent publication highlighted that the combination therapy was associated with changes in growth markers in a small cohort study. This association needs further exploration in randomized study designs.
  • Hospitalization Rates: The compound's activity has been associated with differences in hospital stays in observational research concerning a specific autoimmune disease. These findings are subject to confounding factors inherent in non-randomized studies.

Frequently Asked Questions (FAQ)

Common questions about Lefen (FAQ)


Q: Can Lefen be used for pain relief?

A: Official research evidence has explored the compound's influence on symptoms such as pain and inflammation in individuals with musculoskeletal and neurological conditions, with some studies examining the speed of symptom reduction. However, the primary therapeutic purpose documented in regulatory information is as an antibiotic to treat and prevent bacterial infections.


Q: What groups of people should not use Lefen?

A: According to regulatory documents, Lefen is formally contraindicated for individuals with a known hypersensitivity or allergy to the active ingredient (Lomefloxacin) or any other components in the medicine. Official safety warnings also note increased risks for serious adverse effects in certain groups, including older adults (aged 60 and above), diabetic patients, and those with pre-existing nervous system or heart conditions. Use in these groups is associated with enhanced safety considerations.


Q: Has there been a lot of research done on Lefen?

A: Regulatory bodies and health authorities maintain information derived from extensive studies, including randomized controlled trials (RCTs) and long-term observational research. This evidence is used to understand the compound's profile and use across various patient groups and conditions.


Q: Is Lefen a medication that needs to be tapered off?

A: Official regulatory documents do not contain a general instruction or statement mandating a slow reduction or 'tapering' when the standard course of treatment is completed. Documentation specifies the total duration of a typical course and outlines dosage reduction requirements only for specific conditions, such as kidney impairment.


Q: Can children or teenagers take Lefen?

A: Systemic use of Lefen is officially noted as 'not established' for patients under 18 years of age. Official warnings and studies highlight safety considerations for use in pediatric populations, including potential effects on the musculoskeletal system and changes in growth markers.


Q: Is Lefen the same kind of medicine as [similar drug name]?

A: Lefen is classified by health authorities as a synthetic broad-spectrum antimicrobial agent that belongs to the fluoroquinolone antibiotic class. Other medicines may share this specific classification and mechanism of action, or they may belong to entirely different drug classes that treat different conditions.


Q: What is the difference between Lefen and Tylenol?

A: Lefen (Lomefloxacin) is officially classified as a fluoroquinolone antibiotic used to kill bacterial cells and treat infections. Tylenol (acetaminophen) is classified as an analgesic and antipyretic, meaning its purpose is to relieve pain and reduce fever. These two medicines belong to completely distinct pharmacological classes.


Q: How long does it typically take to feel the effects of Lefen?

A: Official pharmacokinetic data indicates that the elimination half-life of the drug is approximately 8 hours. This measure shows the time required for the body to reduce the active substance level by half. Clinical trials on certain acute infections have also examined the speed of symptom reduction, but individual patient responses may vary.


Q: Does Lefen have a warning about drowsiness?

A: Yes, official regulatory sources document drowsiness as a possible side effect of the medicine. Nervous system disorders are listed in the safety profile, and drowsiness is one of the effects noted.


Q: Can I take Lefen if I am already taking vitamins?

A: Official documents warn that products containing multivalent cations, such as iron, zinc, or calcium, can significantly reduce the absorption of Lefen if consumed too close together. Because many vitamins and supplements contain these minerals, a specific time separation between taking Lefen and these supplements is required.


Q: Is it okay to take Lefen with a cup of coffee?

A: The official regulatory label does not include specific warnings regarding an interaction between Lefen and coffee. However, official pharmacokinetic data for the fluoroquinolone drug class indicates that related compounds can potentially alter the rate at which the body clears caffeine.


Q: Is Lefen suitable for older adults?

A: Official safety information notes that older adults, specifically those aged 60 and above, face an increased risk of severe effects from the medicine, such as tendon rupture. Use in this population is subject to enhanced safety risks documented in official warnings.


Q: Is it possible to become dependent on Lefen?

A: Lefen is an antibiotic and is not classified as a controlled substance by regulatory bodies, which is the classification used for medicines with a potential for dependence or abuse.


Q: Does Lefen affect blood pressure?

A: The regulatory label documents serious cardiovascular risks associated with the drug class, such as QTc interval prolongation (a heart rhythm abnormality) and aortic issues. However, official documentation does not provide a general statement regarding the drug's effect on routine blood pressure measurement.


Q: Can Lefen be taken on an empty stomach?

A: According to the official product information, the oral tablet may be taken without regard to meals. It is not mandatory to consume food at the time of administration.


Q: How is Lefen different from a placebo in clinical trials?

A: Lefen is established to have a bactericidal action, meaning it actively kills bacterial cells. This is achieved by inhibiting essential bacterial enzymes, a mechanism that leads to the destruction of the bacterial cell structure. A placebo is an inactive substance and does not possess this therapeutic action.


Q: What are the ingredients in Lefen besides the active one?

A: Official product labeling lists both the active ingredient, Lomefloxacin, and the inactive ingredients, known as excipients, in the formulation. These excipients are compounds used to form the tablet or solution and are typically listed in the regulatory documents.


Q: How long does Lefen stay in the body after stopping its use?

A: The elimination half-life of Lefen is officially documented to be approximately 8 hours. The half-life is the time required for the concentration of the drug in the body to be reduced by half. Complete clearance from the body requires several half-life periods.


Q: Are there different strengths or versions of Lefen available?

A: Official regulatory documents confirm that Lefen is manufactured as a 400 mg film-coated tablet for oral use. It is also available as a sterile solution designed for localized topical applications in the eye or ear.


Q: Is a prescription required to get Lefen?

A: Yes, Lefen (Lomefloxacin) is regulated by health authorities as a prescription-only legend drug. This means it requires authorization from a licensed healthcare professional for use.


Q: Are there restrictions on driving while using Lefen?

A: Official warnings on nervous system effects, such as dizziness and tremor, indicate that caution is advised regarding operating machinery or driving. These effects may potentially impair mental alertness or coordination.


Q: What is the pregnancy safety category for Lefen?

A: Lefen has been assigned to Pregnancy Category C by the U.S. Food and Drug Administration (FDA). This classification indicates that use should be carefully assessed due to the potential for risk, based on animal studies.


Q: Does Lefen cause stomach upset?

A: Gastrointestinal issues are documented as common side effects in official safety documents. These commonly reported issues include general stomach upset, nausea, diarrhea, and abdominal pain.


Q: Is it common to feel tired when starting Lefen?

A: Fatigue and tiredness are not listed in the 'Common' side effect categories in regulatory documents. However, official warnings have noted the less common occurrence of symptoms like fatigue, somnolence (drowsiness), and sleep disorders in association with the drug class.


Q: Is it normal to have mild changes in sleep when taking Lefen?

A: Insomnia, which is a difficulty with sleeping, is an officially documented side effect of Lefen. In official regulatory texts, this side effect is typically categorized as 'Uncommon' or 'Rare'.


Q: What are the official restrictions for using Lefen?

A: Official restrictions cover several areas, including formal contraindication for hypersensitivity. They also cover general constraints against use in patients under 18 years of age for systemic treatment and mandated time separation rules when taking the drug with multivalent cations.


Q: Is there a generic version of Lefen available?

A: The active ingredient in Lefen is Lomefloxacin. Following the expiration of patent and exclusivity rights, generic versions of medicines containing this active ingredient are typically available, as documented in regulatory publications.


Q: How is the safety of Lefen monitored after it's approved?

A: Official government agencies require ongoing post-marketing surveillance, which is a system also known as pharmacovigilance. This involves the continuous collection and evaluation of spontaneously reported adverse events to monitor and track the drug's safety profile over time.


Q: What are the long-term effects of Lefen use described in documents?

A: Official warnings document rare but serious adverse reactions that are potentially disabling and irreversible, which may occur hours after initiation or months after cessation of treatment. These warnings are based on long-term safety monitoring.


Q: Do other medicines change the way Lefen works?

A: Yes, official labeling describes that other medicines can alter how Lefen works, for example, by reducing its oral absorption or by enhancing specific effects when taken concurrently. The Interactions section of the official label describes these specific effects.


Q: Are there specific diet changes recommended with Lefen?

A: According to official administration instructions, the oral tablet can be taken without regard to meals. However, it is required that the medicine be swallowed whole with a full glass of water.


Q: Why is Lefen sometimes given with another medicine?

A: One of the official indications for Lefen is its use for prophylaxis, which involves a single pre-procedural administration to prevent potential infection. This preventive use is part of the established medical protocol for certain procedures.

How should Lefen be stored and disposed of?

How to Store and Dispose of Lefen?

Lefen must be stored at Controlled Room Temperature, which is between 68 F and 77 F (20 C and 25 C), with excursions permitted to 86 F (30 C). The medicine must be kept in its original container and protected from both moisture and excessive heat.

Storage Requirements

Condition Requirement
Temperature 68 F to 77 F (20 C to 25 C)
Protection Protect from moisture and excessive heat
Safety Keep out of the sight and reach of children

Disposal

Disposal of unused or expired Lefen should be done through a drug take-back program if one is available. If a program is not accessible, the medication may be discarded in the household trash by mixing it with an unappealing substance, sealing the mixture in a container, and disposing of it. Lefen is not on the list of medicines recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lefen found in:

A-Z Index: